PHIA Koninklijke Philips N.V.

Philips and AWS collaborate to scale digital pathology in the cloud, enhancing diagnostic capabilities and improving productivity

Philips and AWS collaborate to scale digital pathology in the cloud, enhancing diagnostic capabilities and improving productivity

March 12, 2024

  • Cloud offering will help improve workflow integration, access, and reliability, delivering greater productivity and collaboration
  • Collaboration combines best of clinical workflow leadership with scalable cloud solution to help accelerate decision-making and further transform patient care

Amsterdam, the Netherlands and Orlando, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an expanded collaboration with Amazon Web Services (AWS) to address the growing need for secure, scalable digital pathology solutions in the cloud. The collaboration unites Philips’ leadership and expertise in digitization of pathology to optimize clinical workflows and AWS’ leadership in scalable, secure cloud solutions.

Philips and AWS will advance digital pathology and help pathology labs to efficiently store, manage, and analyze growing volumes of digital pathology data and enable more pathology labs to adopt digital workflows to increase productivity. In addition, pathology labs will be able to optimize workflow efficiency and facilitate collaboration among specialists, enabling seamless integration with existing healthcare systems to deliver holistic patient care.

Through examination of patient tissue samples, pathology plays a crucial role in the diagnosis and management of a variety of diseases, particularly cancer. With an estimated 70% of important medical decisions involving laboratory or pathology tests [1], the availability of digitally stored pathology images is especially important as it has a significant impact on patient care. The growing need for scalable storage to meet new data volumes and computing resources to power innovative artificial intelligence (AI) models, calls for expanding capabilities of traditional on-premise solutions into the cloud.

“By harnessing the power of the cloud to accelerate the digitization of pathology, we are improving the quality of patient care by enabling greater workflow efficiency and collaboration at scale,” said Shez Partovi, Chief Innovation & Strategy Officer and Chief Business Leader Enterprise Informatics at Philips. “As the demand for pathology-based diagnosis continues to increase, we see digital pathology in the cloud as a critical enabler for productivity, scale and to further transform healthcare diagnostics by opening new avenues for research, education, and the integration of AI to further improve patient care.”

Philips is an provider of digital pathology solutions, with more than 300 customers using the fully digital workflow of . Philips’ collaboration with AWS has the potential to enable large scale clinical trials, multi-institute studies, and care collaboration to address complex cases, including in cancer care. Philips will use to optimize storage, increase scale and enable AI and research across the healthcare system to advance pathology image analysis and simplify clinical workflows. Additionally, Amazon Bedrock, which offers high-performing foundation models (FMs), will support generative AI application development and integration.

“Healthcare organizations benefit when clinical workflow leadership is combined with scalable cloud infrastructure. By building their cloud-native enterprise pathology solution on services like AWS HealthImaging and Amazon Bedrock, Philips is offering their customers the best of both worlds,” said Tehsin Syed, GM of Health AI at AWS. “Secure cloud-based offerings address the growing demand to store and utilize more data, and by digitizing pathology healthcare leaders can apply AI and ML to drive better insights. We look forward to continued work with Philips to help improve productivity, advance research, and ultimately enable more precise and tailored patient care.”  

Combined with on AWS to support radiologists, Philips’ broad capabilities in enterprise informatics enable an integrated diagnostics approach to empower clinicians with improved diagnostic workflows, quicker access to images from any location – helping along the entire workflow across enterprise imaging, from diagnosis to treatment options and follow-up.

For more information on Philips’ informatics solutions and news at HIMSS, please visit or join us in person at the conference, booth #2041 and follow #HIMSS24 for updates.

[1] Report of the Second Phase of the Review of NHS Pathology Services in England, Lord Carter of Coles (2008). Results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions.

For further information, please contact:

Anna Hogrebe

Philips External Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments



EN
12/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

Oscar Rodriguez
  • Oscar Rodriguez

PHILIPS: RDOS. 4T’25 Y CAMBIO DE P.O. AL ALZA (ANÁLISIS BANCO SABADELL...

Rdos. 4T’25 vs 4T’24: Ventas: 5.097 M euros (+1,1% vs -0,9% BS(e) y -1,0% consenso); EBITA Aj.: 770 M euros (+13,4% vs +0,6% BS(e) y -1,0% consenso); BDI: 397 M euros (-333 M euros en 2024 vs 275 M euros BS(e) y 276 M euros consenso); Rdos. 2025 vs 2024: Ventas: 17.834 M euros (-1,0% vs -1,6% BS(e) y -1,6% consenso); EBITA Aj.: 2.195 M euros (+5,7% vs +1,5% BS(e) y +1,0% consenso); BDI: 897 M euros (-698 M euros en 2024 vs 775 M euros BS(e) y 776 M euros consenso).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch